EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Survival assessment and pre-diagnostic risk factors for lung cancer incidence: Insights from the Golestan Cohort Study

Seyedeh Fatemeh Mousavi, Sahar Masoudi, Negar Rezaei, Farzad Pourghazi, Maryam Sharafkhah, Maysa Eslami, Akram Pourshams, Hossein Poustchi, Gholamreza Roshandel iD, Rasoul Aliannejad, Sadaf G Sepanlou iD, Reza Malekzadeh

PLOS One · 29.04.2025 · 20 (4) · e0320931

DOI: 10.1371/journal.pone.0320931 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PLOS One, online erschienen am 29.04.2025. Verfasst von Seyedeh Fatemeh Mousavi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung cancer remains a pressing health issue globally. This study investigates survival rates and the impact of pre-diagnostic factors on lung cancer incidence in Golestan Cohort Study (GCS).

Method

The GCS, initiated in 2004 with enrollment concluding in 2008, comprises 49,783 individuals aged 40–75 from the Golestan province in northeastern Iran. Our analysis included all cases of lung, tracheal, and bronchial cancers diagnosed under ICD-10 codes C33-C34 from the study’s inception to 2022, tracking participants until death. A sensitivity analysis, excluding lung cancer cases diagnosed within the initial 24 months of follow-up, was performed to address the reverse causation bias from previously undiagnosed conditions at baseline.

Results

Out of 49,783 participants in the study, 132 were diagnosed with lung cancer, of whom 130 died by the end of the study. The age and sex-standardized incidence rate stood at 20.39 per 100,000 person-years. The median survival post-diagnosis was approximately four months, with one-year and five-year survival rates at 18.67% and 1.56%, respectively. Sensitivity analyses identified advanced age, male sex, opiate use history, pack-years of cigarette smoking, and the utilization of non-gaseous energy sources as lung cancer risk factors. In contrast, high physical activity and a BMI of 25 or higher were inversely associated with lung cancer risk.

Conclusion

Our study highlights the critical burden and low survival rates of lung cancer in resource-limited regions. Mitigating key risk factors and enhancing access to diagnostic and treatment services through targeted public health policies and comprehensive strategies are essential for ensuring equitable healthcare and improving lung cancer outcomes for underserved populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsHumansMaleMiddle AgedFemaleAgedRisk FactorsIncidenceAdultIranCohort StudiesSurvival RateSurvival Analysis

Autor:innen und Institutionen

  • Digestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.
  • Advanced Thoracic Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Division of Pulmonary and Critical Care, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Gholamreza Roshandel, Sadaf G Sepanlou

Zitieren

APA

Mousavi, S. F., Masoudi, S., Rezaei, N., Pourghazi, F., Sharafkhah, M., Eslami, M., Pourshams, A., Poustchi, H., Roshandel, G., Aliannejad, R., Sepanlou, S. G., & Malekzadeh, R. (2025). Survival assessment and pre-diagnostic risk factors for lung cancer incidence: Insights from the Golestan Cohort Study. PLOS One, 20(4), e0320931. https://doi.org/10.1371/journal.pone.0320931

Vancouver

Mousavi SF, Masoudi S, Rezaei N, Pourghazi F, Sharafkhah M, Eslami M, et al. Survival assessment and pre-diagnostic risk factors for lung cancer incidence: Insights from the Golestan Cohort Study. PLOS One. 2025;20(4):e0320931. doi:10.1371/journal.pone.0320931

BibTeX
@article{Mousavi2025,
  author = {Mousavi, Seyedeh Fatemeh and Masoudi, Sahar and Rezaei, Negar and Pourghazi, Farzad and Sharafkhah, Maryam and Eslami, Maysa and Pourshams, Akram and Poustchi, Hossein and Roshandel, Gholamreza and Aliannejad, Rasoul and Sepanlou, Sadaf G and Malekzadeh, Reza},
  title = {Survival assessment and pre-diagnostic risk factors for lung cancer incidence: Insights from the Golestan Cohort Study},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {4},
  pages = {e0320931},
  doi = {10.1371/journal.pone.0320931}
}
Kostenlos starten →